Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013, Article ID 759476, 10 pages
Research Article

Xiaoqinglong Granules as Add-On Therapy for Asthma: Latent Class Analysis of Symptom Predictors of Response

1School of Computer, Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, China
2Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China
3Division of Allergy and Immunology, Thomas Jefferson University, Wilmington, DE 19803, USA
4Department of Respiratory Medicine, Affiliated Hospital of Jiangxi University of TCM, Nanchang 330004, China
5Department of Respiratory Medicine, People's Hospital of Jiangxi Province, Nanchang 330006, China
6Department of Respiratory Medicine, The First Affiliated Hospital of Gannan Medical University, Gannan 314000, China
7Department of Respiratory Medicine, The Third Affiliated Hospital of Nantong University, Nantong 216000, China
8Department of Respiratory Medicine, Nanchang Hospital of Integrated Traditional Chinese and Western Medicine, Nanchang 330003, China
9Department of Respiratory Medicine, The First Affiliated Hospital of Guangzhou University of TCM, Guangzhou 510405, China
10School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Kowloon, Hong Kong

Received 30 July 2012; Accepted 3 December 2012

Academic Editor: Haruki Yamada

Copyright © 2013 Qinglin Zha et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Xiaoqinglong granules (XQLG) has been shown to be an effective therapy in asthma animal models. We reviewed the literature and conducted this study to assess the impact of XQLG as an add-on therapy to treatment with fluticasone/salmeterol (seretide) in adult patients with mild-to-moderate, persistent asthma. A total of 178 patients were randomly assigned to receive XQLG and seretide or seretide plus placebo for 90 days. Asthma control was assessed by asthma control test (ACT), symptoms scores, FEV1, and PEF. Baseline patient-reported Chinese medicine (CM)-specific symptoms were analyzed to determine whether the symptoms may be possible indicators of treatment response by conducting latent class analysis (LCA). There was no statistically significant difference in ACT score between two groups. In the subset of 70 patients with symptoms defined by CM criteria, XQLG add-on therapy was found to significantly increase the levels of asthma control according to global initiative for asthma (GINA) guidelines ( ). There was no significant difference in another subset of 100 patients with relatively low levels of the above-mentioned symptoms ( ). Results of LCA suggest that patients with the six typical symptoms defined in CM may benefit from XQLG.